About Dhiti Omics
Dhiti Omics is a company based in Bengaluru (India) founded in 2014. Dhiti Omics has raised $278.39 thousand across 2 funding rounds from investors including Harkaran Dhingra, Raja Mugasimangalam and Vasanthammal. Dhiti Omics operates in a competitive market with competitors including Foundation Medicine, Personalis, Omniome, Novogene Corporation and MedGenome, among others.
- Headquarter Bengaluru, India
- Stage Minicorn
- SectorsHealthcare
- Website dhitiomics.com
- Social LinkedIn X Facebook Instagram
- Legal Name Dhiti Omics Technologies Private Limited
- Date of Incorporation 24 Jun, 2014
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹7.24 Cr
FY 2025 · +342% YoY
- Net Profit₹2.52 Cr
FY 2025 · 35% margin
- EBITDA₹2.66 Cr
FY 2025 · 37% margin
- Total Equity Funding$278.39K (USD)
in 2 rounds
- Latest Funding Round$105.1K (USD), Angel Round
Oct 2022
Associated legal entities of Dhiti Omics
Dhiti Omics operates through Dhiti Omics Technologies Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Dhiti Omics Technologies Private Limited CIN U24100KA2014PTC075038 | Active | 24 Jun 2014 | Bangalore, Karnataka | ₹7.2 Cr | – | 2 | View details |
Funding Insights of Dhiti Omics
Dhiti Omics has successfully raised a total of $278.39K across 2 strategic funding rounds. The most recent funding activity was a Angel Round of $105.1 thousand completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $278,388
- Total Rounds 2
- Last Round Angel Round — $105,100
- First Round $173,288
(Mar 2016)
- Investors Count 9
All 2 funding rounds of Dhiti Omics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2022 | $105,100 | Angel Round | $1.74M | Harkaran Dhingra, Raja Mugasimangalam | – |
| Mar 2016 | $173,288 | Angel Round | $1.63M | Sundaram Subramanian, Shankar Srinivasan |
| Date | Valuation | Stage |
|---|---|---|
| Oct 2022 | $1.74M | •••••••• |
| Mar 2016 | $1.63M | •••••••• |
Last known valuation $1.74M (Oct 2022). 9 investors in total: 0 institutional and 9 angel.
Investors in Dhiti Omics
Dhiti Omics has secured backing from 9 investors, including angel investors. Prominent investors backing the company include Harkaran Dhingra, Raja Mugasimangalam and Vasanthammal.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
HD Harkaran Dhingra | - | – | unknown_267172623f604fd4b | - |
RM Raja Mugasimangalam | - | – | unknown_9e241ed6be25405ea | - |
V Vasanthammal | - | – | unknown_ebfeb272af5d429d9 | - |
U Umarani | - | – | unknown_8919577b3bed49598 | - |
SP Saradha Periannan | - | – | unknown_9ca6f0fae2fe4ecab | - |
SS Sundaram Subramanian | - | – | unknown_0cb5e6c63dde4cf68 | - |
AR Amutha Ramakrishnan | - | – | unknown_074b44fd07df47278 | - |
SS Shankar Srinivasan | - | – | unknown_c362b0a662644a469 | - |
MS Muthu Subramanian | - | – | unknown_0cace4f661684fc5b | - |
Investor details for Dhiti Omics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Dhiti Omics Technologies Private Limited (Dhiti Omics)
Dhiti Omics Technologies Private Limited is the primary company behind Dhiti Omics. The board of Dhiti Omics Technologies Private Limited currently have 2 directors; the longest-serving is Sudha Narayan Rao, appointed in 2014. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sudha Narayan Rao DIN 01726325 | Director | 24 Jun 2014 | 12 yrs 3 mo | Dhiti Omics Technologies Private Limited |
| Ramesh Kannan DIN 00513755 | Director | 24 Jun 2014 | 12 yrs 3 mo | Dhiti Omics Technologies Private Limited |
Financials of Dhiti Omics
Figures of Dhiti Omics Technologies Private Limited, the primary company behind Dhiti Omics, for FY 2025. Revenue was ₹7.24 Cr (+342% year on year). Net profit was ₹2.52 Cr (35% margin). EBITDA was ₹2.66 Cr (37% margin). Revenue has grown at a compounded annual rate of +80% over three years and +57% over five years.
- ₹7.24 CrRevenue · FY 2025 · +342% YoY
- ₹2.52 CrNet profit · 35% margin
- ₹2.66 CrEBITDA · 37% margin
- ₹18.7 LakhPaid-up capital
- +80%Revenue CAGR, 3 years
- +57%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Dhiti Omics Technologies Private Limited are on its company page.
Detailed financial statements for Dhiti Omics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Dhiti Omics
4 dated milestones of Dhiti Omics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Dhiti Omics is founded.
- Funding First funding round of $173K.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Angel Round, of $105K.
Competitors of Dhiti Omics
Dhiti Omics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Foundation Medicine, Personalis, Omniome, Novogene Corporation and MedGenome, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| personalis.com | 2011 | Menlo Park, United States | $87.3M | 310 | Genomic sequencing and diagnosis software is provided for healthcare. | |
| omniome.com | 2013 | San Diego, United States | $160.23M | 164 | Genome sequencing platform is provided for clinical diagnostics. | |
| novogene.com | 2011 | Beijing, China | $75M | 141 | Genomic services and solutions with NGS expertise are provided. | |
| medgenome.com | 2013 | Bengaluru, India | $264.5M | 922 | DNA sequencing, bioinformatics, and multiomics services are provided. | |
| tesseratherapeutics.com | 2017 | Cambridge, United States | $610M | 149 | New genome engineering technology is provided for treating multiple diseases. | |
| lanternpharma.com | 2013 | Dallas, United States | $7.12M | 23 | Drug and companion diagnostics for multi-drug resistant cancers are developed. | |
| phasegenomics.com | 2015 | Seattle, United States | $5.75M | 19 | Laboratory and computational services for DNA proximity analysis are provided. | |
| brbiotech.com | 2014 | Guangzhou, China | $203.32M | – | Personalized cancer diagnostics are developed using genomic big data analysis. | |
| hitgen.com | 2012 | Lanzhou, China | $39.11M | – | DNA-encoded libraries are developed for drug discovery applications. |
Detailed competitors of Dhiti Omics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dhiti Omics
Complete news archive for Dhiti Omics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Dhiti Omics
10 companies that operate in the same segment as Dhiti Omics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Dhiti Omics
Dhiti Omics was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Dhiti Omics is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Dhiti Omics is a funded company, having raised a total of $278.39K across 2 funding rounds to date. The company's 1st funding round was a Angel Round of $173.29K, raised on Mar 2016.
The primary company behind Dhiti Omics, Dhiti Omics Technologies Private Limited, reported revenue of ₹7.24 Cr for FY 2025, up 342% year on year.
Dhiti Omics was founded in 2014 and is based in Bengaluru, India. Operations focus on the molecular diagnostics sector, where state-of-the-art methods such as Sanger Sequencing, Next Generation Sequencing, and Microarrays are utilized. These technologies are applied to analyze individual genomes and detect genetic indicators. Clinicians are supported in disease prediction, prevention, and informed patient decision-making through these services.
Dhiti Omics's top competitors include Foundation Medicine, MedGenome and Personalis.
Dhiti Omics has 9 investors. Key investors include Harkaran Dhingra, Raja Mugasimangalam, Vasanthammal, Umarani, and Saradha Periannan.
The valuation of Dhiti Omics is $1.74M as of Oct 2022.
Dhiti Omics operates through Dhiti Omics Technologies Private Limited.
The legal entities of Dhiti Omics currently have 2 directors, including Sudha Narayan Rao, Ramesh Kannan.